Skip to main content

Jordi Bove Badell

I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Jordi Bove Badell

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.

I received a Pharmacy degree from the University of Barcelona in 1998. In 2003, I got a PhD in Pharmacy (Neurobiology) with cum laude distinction from the same university at the Experimental Neurology Laboratory, Neurological Service of Hospital Clínic de Barcelona-IDIBAPS (Dr. C. Marin/Prof. E. Tolosa). My doctoral thesis shed light on the mechanism of levodopa-induced motor fluctuations in Parkinson's disease. I later joined the laboratory of Dr. Serge Przedborski at Columbia University (New York, USA) as a post-doctoral researcher (2003-2005), working on animal modeling and the role of alpha-synuclein in Parkinson's disease. In 2006 I co-founded the Neurodegenerative Diseases Research Group at Vall d’Hebron Research Institute (VHIR) in the Vall d’Hebron Hospital Campus (Barcelona) with its leader Dr. Miquel Vila. In 2011, I obtained a position as a Miguel Servet Investigator (Instituto de Salud Carlos III, Spain) as a Researcher in the National System of Health, and since then I am one of the principal investigators of the group. The research that I am leading is aimed to elucidate the mechanism of neuron cell death and to determine new therapeutic targets to develop neuroprotective strategies for Parkinson’s disease and other neurodegenerative diseases. I am also interested in establishing presymptomatic biomarkers of Parkinson´s disease. I am currently focused on the role of the adaptive immune system in Parkinson’s disease. Our latest published study suggests that a cytotoxic attack induced by CD8 T lymphocytes initiates the disease.

Projects

INCORPORACIÓ D'UN TÈCNIC DE LABORATORI PEL DESENVOLUPAMENT DE TERÀPIES NEUROPROTECTORES I EINES DE DIAGNÒSTIC PRESIMPROMÀTIC PER A LA MALALTIA DE PARKINSON

IP: Jordi Bove Badell
Collaborators: Laia Perez Lasarte
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00258
Duration: 14/03/2018 - 12/05/2019

Sol·licitud Miguel Servet II

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 91125
Reference: CPII16/00029
Duration: 01/01/2017 - 31/12/2019

Títol tesi: Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación, diagnóstica y terapéutica

IP: Jordi Bove Badell
Collaborators: Laia Perez Lasarte
Funding agency: Fundación Tatiana Pérez de Guzmán el Bueno
Funding: 98400
Reference: TATIANA/PREDOC/NEURO/2016/GALIANO
Duration: 01/12/2016 - 31/12/2020

Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación diagnóstica y terapéutica

IP: Jordi Bove Badell
Collaborators: Oriol de Fabregues-Boixar Nebot
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI15/01937
Duration: 01/01/2016 - 31/12/2018

Related news

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Related professionals

Iratxe Ugarriza Serrano

Iratxe Ugarriza Serrano

Neurovascular Diseases
Read more
M. Mercè Fabregat  Bosch

M. Mercè Fabregat Bosch

Reconstructive Surgery of the Locomotor System
Read more
José Alonso Fajardo

José Alonso Fajardo

Shock, Organ Dysfunction and Resuscitation
Read more
Eulàlia Pérez Esquirol

Eulàlia Pérez Esquirol

Senior researcher
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.